# Study of Sargramostim in Moderately to Severely Active Crohn's Disease

> **NCT00329537** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 11 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Sargramostim (Leukine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00329537
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329537, "Study of Sargramostim in Moderately to Severely Active Crohn's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00329537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*